Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Opaleye Management Inc. Purchases 11,715 Shares

Harrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. bought 11,715 shares of the firm's stock in a transaction that occurred on Tuesday, April 23rd. The stock was purchased at an average price of $10.29 per share, for a total transaction of $120,547.35. Following the completion of the transaction, the insider now directly owns 3,786,715 shares of the company's stock, valued at approximately $38,965,297.35. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Friday, April 19th, Opaleye Management Inc. purchased 29,400 shares of Harrow Health stock. The shares were acquired at an average cost of $10.56 per share, for a total transaction of $310,464.00.
• On Thursday, March 28th, Opaleye Management Inc. acquired 50,000 shares of Harrow Health stock. The shares were bought at an average cost of $12.82 per share, for a total transaction of $641,000.00.
• On Wednesday, March 20th, Opaleye Management Inc. bought 50,600 shares of Harrow Health stock. The stock was bought at an average price of $9.65 per share, with a total value of $488,290.00.

Harrow Health Price Performance

Harrow Health stock traded down $0.05 during mid-day trading on Wednesday, reaching $10.27. 406,218 shares of the company traded hands, compared to its average volume of 443,338. Harrow Health, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $28.25. The firm's fifty day moving average is $11.57 and its two-hundred day moving average is $11.27. The company has a current ratio of 2.83, a quick ratio of 2.61 and a debt-to-equity ratio of 2.60.

Harrow Health (NASDAQ:HROW - Get Free Report) last issued its earnings results on Tuesday, March 19th. The company reported ($0.27) earnings per share (EPS) for the quarter. Harrow Health had a negative return on equity of 29.48% and a negative net margin of 18.75%. The firm had revenue of $36.36 million during the quarter, compared to analysts' expectations of $37.65 million. Sell-side analysts anticipate that Harrow Health, Inc. will post -0.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Rice Hall James & Associates LLC increased its holdings in Harrow Health by 5.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 245,101 shares of the company's stock worth $3,243,000 after acquiring an additional 13,637 shares in the last quarter. Drive Wealth Management LLC purchased a new stake in Harrow Health during the 1st quarter worth approximately $240,000. Wasatch Advisors LP raised its holdings in shares of Harrow Health by 28.3% during the first quarter. Wasatch Advisors LP now owns 388,132 shares of the company's stock valued at $5,135,000 after acquiring an additional 85,600 shares during the last quarter. Woodmont Investment Counsel LLC raised its stake in Harrow Health by 73.3% in the 1st quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company's stock valued at $2,799,000 after purchasing an additional 89,510 shares during the last quarter. Finally, Private Capital Management LLC lifted its holdings in Harrow Health by 97.2% in the 4th quarter. Private Capital Management LLC now owns 2,794,497 shares of the company's stock valued at $31,298,000 after purchasing an additional 1,377,597 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HROW has been the subject of a number of analyst reports. Craig Hallum initiated coverage on Harrow Health in a research report on Thursday, April 11th. They issued a "buy" rating and a $24.00 price target for the company. B. Riley decreased their price target on Harrow Health from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, March 22nd.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.